Meeting Highlights from Heart In Diabetes 2019

July 12-14, 2019
Lowe's Philadelphia Hotel Philadelphia, PA

Organized by the Metabolic Institute of America, the third annual Heart in Diabetes conference was conceived to address the growing need to manage the complex challenges arising with heart disease in people with diabetes.

The Heart in Diabetes 2019 program aimed to inform clinicians about evidence based clinical research, precision medicine planning, and the implications of the results in advancing patient care. Equally important to the organizing committee is the need to align endorinologists, cardiologists, lipidolgists, nephrologists, hepatologists, and primary care practitioners in understanding the full range of issues facing this complex patient population and the need to develop multidisciplinary management approaches necessary in lessening the adverse outcomes of this high risk population.

The three days are devoted to examining the latest trials and evolving science in a comprehensive manner with consideration of the gains and gaps in knowledge with regard to the cardivascular implications of blood glucose regulation, dyslipidemia, hypertension, and inflammation.  

Attendees are afforded the opporutnity to explore varied clinical persepctives impacting pateints with concommitant cardiovascular disease and diabetes from the vantage points of cardiology, endocrinology, and nephrology.

Select topics addressed in this three-day continuing education conference:

  • Exploring the interrelationship of obesity, diabetes and the heart in the development of kidney disease, retinopathy, cardiovascular disease, and arrthymias
    Hyperlipidemia: Treatment considerations for high triglycerides, HLC-cholesterol, and how low to go with LDL
  • Blood glucose: Implications of hypoglycemia and hyperglycemia
  • Chronic heart failure
  • Athersoclorosis
  • Non-alcoholic fatty liver disease: Understanding management options along the disease continuum 
  • Kidney disease: How treatment should be adjusted to the stage of disease
  • Considering big data and the implications of results from key outcomes trials in tailoring treatment to the individual patient

EndocrineWeb reports on location, featuring video highlights that include three exclusive interviews with attendees who share their "ah ha" moments regarding practice advances that clicked with them from presentations that they say will change the way they plan to manage certain patients differently going forward:

Pallavy G. Reddy, MD, FACE, a clinical endocrinologist in private practice in Dublin, Ohio, was particularly focused on the need to address the risks of peripheral artery disease in patients with type 2 diabetes as this condition is an equal partner in the constellation of conditions that make up athersclerotic heart disease.

John J. Reusch, MD, a cardiologist at Colorado Permanente Medical Group in Denver, Colorado, traveled to learn more about the growing array of new medications that offer dual and even multiple disease benefits in patients with diabetes and cardiovascular disease.

Gina Slobogin, DNP, APRN, FNPL-BC, a nurse practitioner in private practice found the preliminary work on troponin as a biomarker of hypoglycemia in patients with CVD particularly interesting given her experinece in diagnosing myocardial infarctions while an emergency department nurse; she saw lots of merit in obtaining background troponin levels so when patients are admitted to the ED, the medical staff might be able to make a quick determination of the need to address hypoglyemia rather than have to escalate a work up for a false cardiac event.

We also share highlights from several presentations including an exclusive video interview with Michael H. Davidson, MD, who began the conference with a presentation examining the role of inflammation in heart disease and non-athersclerotic cardiovascualar events in patients with diabetes.


Last updated on
First Article From This Meeting:
Blocking Cytokine Pathway Promises Best Intervention for Diabetes, CVD
close X